Synonym |
Thai / English name |
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : EGb761Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 50 (M/F=50/-)N(Treatment) : 50 (M/F=50/-)Sex : MaleAge : 20-44 yrs. (mean 27.2+/-4.9)Route : Oral administrationDose/Conc.(herb) : EGb 761 120 mg of dry extract twice dailyDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : 500 mg dailyResult : PositiveRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : EGb761Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 50 (M/F=50/-)N(Treatment) : 50 (M/F=50/-)Sex : MaleAge : 20-44 yrs. (mean 27.2+/-4.9)Route : Oral administrationDose/Conc.(herb) : EGb 761 120 mg of dry extract twice dailyDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : 500 mg dailyResult : PositiveRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : Ginkgo biloba special extraction (EGb 761)Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 50N(Treatment) : 50Sex : MaleAge : 20-44 yearsRoute : Oral administrationDose/Conc.(herb) : *Duration : **Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : EquivocalRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA +EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of means 1.01, 90% Cl 0.86, 1.19) and agonist - induced platelet aggregation (collagen - induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00, 90% Cl 0.95, 1.05; ADP-induced platelet aggregation -ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06).Note : *Dose: Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo - coated tablate in the morning and placebo tablet + placebo - coated tablet in evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg - coated tablet in the morning and placebo tablet + EGb 761 120 mg - coated tablet in evening. **Duration: Each treatment lasted 7 days, the washout period between treatment was 3 weeks. - Data incomplete.